Treating Cancer-Related Fatigue Through Systematic Light Exposure (Light for Fatigue Study)
NCT03119363 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 194
Last updated 2022-06-16
Summary
Cancer related fatigue (CRF) is the most common cancer side effect and can severely interfere with activities of daily living long after completion of medical treatment. Pharmacologic agents to treat CRF have been studied but there is insufficient evidence to recommend their use. Non-pharmacological interventions for CRF have also been studied but are costly to implement and involve significant patient burden. This study investigates a novel low-cost/ low-burden intervention: systematic light exposure to treat CRF. Two hundred survivors of multiple myeloma and Diffuse Large B-cell Lymphoma between 1 month and 5 years post-autologous stem cell transplant (ASCT) will be recruited from three medical centers. The light will be administered by a small, personal light glasses daily for 4 weeks. Outcomes will be assessed at five separate time points, including baseline and follow-up. The study will specifically address recommendations made for interventions for CRF from the NCI Clinical Trials Planning meeting (JNCI, 2013).The proposed study will: 1) be the first large multisite study with a carefully delineated comparison condition to investigate the effects of light on CRF among ASCT survivors; 2) focus on a distinct, homogenous patient population; 3) include only survivors who experience clinical levels of CRF; and 4) address possible psychological and biological mechanisms. This study will have major public health relevance as it will determine if an easy-to-deliver, inexpensive, and low patient burden intervention effectively reduces CRF.
Conditions
Interventions
- DEVICE
-
AYO light glasses (Experimental)
The AYO does not contain UV or infra-red light; the light spectrum begins at approximately 420nm. The circadian-effective AYO is programed at over 100 lux with 470nm frequency and irradiance of 250 qW/cm2, which is 100% intensity level. Irradiance over lux itself with AYO light glasses is believed to be more representative due to light frequency and proximity to the eye. Traditional Lightbox usual measure is Lux , AYO can be seen as comparable to 1,000 lux light box. The device is classified as a device that is safe for the eyes in accordance with the international standard IEC 62471 and is independently certified by TÜV Rheinland. AYO complies with the EU's CE marking (CE EMC EN 55014, EN 61000-4-3) as well as other national regulatory directives. AYO also complies with the United States of America's FCC marking (FCC Title 47, Chapter 1, Part 15, Class B FCC VOC: 47 CFR PART 15 OCT, 2016. CLASS B ANSI C 63.4: 2014) as well as other national marking regulatory directives.
- DEVICE
-
AYO light glasses (Comparator)
The comparison group will wear the same AYO glasses, but with a circadian ineffective (sham) light. The circadian-ineffective (sham) is programed at 1% intensity, therefore according to our calculation and checks it is below circadian threshold of 2 lux as specified.
Sponsors & Collaborators
-
Memorial Sloan Kettering Cancer Center
collaborator OTHER -
Hackensack Meridian Health
collaborator OTHER -
Icahn School of Medicine at Mount Sinai
lead OTHER
Principal Investigators
-
William H Redd, PhD · Icahn School of Medicine at Mount Sinai
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-09-01
- Primary Completion
- 2022-04-01
- Completion
- 2022-04-01
Countries
- United States
Study Locations
More Related Trials
-
Celecoxib in Preventing Skin Cancer
NCT00025051 ·Status: WITHDRAWN ·Phase: PHASE2
-
Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT02100423 ·Status: COMPLETED ·Phase: PHASE2
-
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
NCT01014546 ·Status: TERMINATED ·Phase: PHASE1
-
Correlative Biomarker Study in Patients With Myeloproliferative Disorders
NCT00665067 ·Status: COMPLETED
-
Cyclophosphamide and Celecoxib in Treating Patients With Advanced Cancer
NCT00551889 ·Status: COMPLETED ·Phase: PHASE1
-
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
NCT00088972 ·Status: TERMINATED ·Phase: PHASE2
-
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
NCT06987708 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses
NCT00027976 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3
-
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan
NCT02030964 ·Status: COMPLETED ·Phase: PHASE1
-
Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma
NCT03068637 ·Status: COMPLETED ·Phase: NA
-
Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
NCT00101335 ·Status: COMPLETED ·Phase: PHASE2
-
Effect of CoQ10 Plus Selenium Supplementation on Clinical Outcomes and Biochemical Markers in ME/CFS (CoSeME Study)
NCT05128292 ·Status: COMPLETED ·Phase: NA
-
Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients
NCT01269203 ·Status: WITHDRAWN ·Phase: PHASE2
-
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
NCT04549363 ·Status: TERMINATED ·Phase: PHASE3
-
COMPASS Study for Metastatic Castration-resistant Prostate Cancer
NCT07050433 ·Status: RECRUITING
-
Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses
NCT03185871 ·Status: WITHDRAWN ·Phase: PHASE2
-
Biomarkers in Samples From Patients With Chronic Lymphocytic Leukemia Treated on Clinical Trial ECOG-2997
NCT00899873 ·Status: COMPLETED
-
Autoimmunity After Checkpoint Blockade
NCT04119713 ·Status: RECRUITING
-
Quality of Life and Symptoms in Patients With Newly Diagnosed Myelodysplastic Syndromes
NCT00809575 ·Status: UNKNOWN
-
Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci)
NCT00365209 ·Status: COMPLETED ·Phase: PHASE2
-
Moving Foward With Myeloma (MFM)
NCT07236502 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors
NCT06028022 ·Status: RECRUITING ·Phase: PHASE2
-
Celecoxib in Preventing Lung Cancer in Former Heavy Smokers
NCT00055978 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
NCT05184816 ·Status: RECRUITING ·Phase: PHASE1
-
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
NCT00093678 ·Status: WITHDRAWN ·Phase: NA